Historical record - last NADAC effective date: 8/22/2013
Product Information
TAZICEF 2 GRAM VIAL is a generic product labeled by Hospira Inc., priced at $9.5080 per EA under NDC 00409508411. Its NADAC has been published 42 times since Nov 28, 2013.
FDA first approved this application on Mar 6, 1986. Its Orange Book therapeutic-equivalence code is AP.
Strength
2 g/1
Manufacturer
Hospira Inc.NDC
00409508411
Classification
Generic
Dosage Form
INJECTION, POWDER, FOR SOLUTION
Route
INTRAVENOUS
Effective Date
8/22/2013
Active Ingredients
CEFTAZIDIMEApproval Type
Generic (ANDA)
FDA Application
ANDA062662FDA Approved
3/6/1986
TE Code
AP
On Market Since
12/16/2005
Pharmacological Classes
Price Statistics
The NADAC for TAZICEF 2 GRAM VIAL has been published 42 times since Nov 28, 2013, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $9.5080 per EA |
|---|---|
| All-time high | $9.5080 (Sep 10, 2014) |
| All-time low | $9.5080 (Nov 28, 2013) |
| Median price | $9.5080 |
| Average price | $9.5080 |
| Largest weekly change | 0.0% (Dec 5, 2013) |
| Weeks tracked | 42 |
| Tracking since | Nov 28, 2013 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
N/A
All
0.0%
Last surveyed Sep 10, 2014 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the CEFTAZIDIME market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Hospira Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
CEFTAZIDIME market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Cephalosporin Antibacterial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TAZICEF 2 GRAM VIAL?
The current National Average Drug Acquisition Cost (NADAC) for TAZICEF 2 GRAM VIAL, manufactured by Hospira Inc., is $9.5080 per EA (NDC 00409508411), effective Sep 10, 2014.
How has the price of TAZICEF 2 GRAM VIAL changed over time?
Over the history we have for it, the NADAC for TAZICEF 2 GRAM VIAL has held within roughly two percent of its current level. It has been tracked across 42 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for TAZICEF 2 GRAM VIAL?
Since Nov 28, 2013, the NADAC for TAZICEF 2 GRAM VIAL has ranged from a low of $9.5080 (Nov 28, 2013) to a high of $9.5080 (Sep 10, 2014), with a median of $9.5080 per EA.
Are there cheaper alternatives to TAZICEF 2 GRAM VIAL?
No other NADAC-published product currently shares the active ingredient and strength of TAZICEF 2 GRAM VIAL in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures TAZICEF 2 GRAM VIAL?
TAZICEF 2 GRAM VIAL (NDC 00409508411) is labeled by Hospira Inc., and CMS classifies it as a generic product.